Effects Of SGLT-2i On HbA1c And BP In Patients With Type 2 Diabetes Mellitus And Hypertension In Xining Area

Objective: This study aims to explore the therapeutic effect and clinical value of SGLT-2i on T2 DM patients with hypertension in Xining area.Dagaglizin will be used as a representative drug to further study the effects of SGLT-2i on Hb A1 c and BP,so as to provide appropriate treatment for patients with poor control of blood glucose and BP in Xining area.Methods:A total of 80 T2 DM patients with hypertension who visited the Department of Endocrinology,Affiliated Hospital of Qinghai University from October 2020 to December 2021 were selected.Meanwhile,metformin hydrochloride tablets were required to take single-drug hypoglycemic therapy regularly during the course of individual disease.Patients were divided into experimental group and control group according to random number table method,with 40 cases in each group.Control group continued to take metformin hydrochloride tablets,0.5g each time,3 times a day.Experimental group was additionally given dagaglizin,10 mg each time,once a day,on the basis of control group.Both groups were treated for 12 weeks.Changes in FBG,2h PBG,Hb A1 c,SBP,DBP,RBC,HB,HCT,body weight,BMI,TC,TG,HDL-C,LDL-C and UA were observed and compared between the two groups before and after treatment,and adverse reactions related to this study were recorded.Results: Finally,78 patients successfully completed the study(38 in the experimental group and 40 in the control group),and 2 patients were excluded from the experimental group.During the follow-up period,1 patient failed to regularly follow up and monitor blood glucose and blood pressure due to poor dependency,and 1 patient was lost to follow-up during the course of follow-up.There were no significant differences in gender,age,DM course,body weight,BMI,FBG,2h PBG,Hb A1 c,SBP,DBP and other related indicators between the two groups.The results showed as follows:(1)After 12 weeks of treatment,BMI,FBG,2h PBG,Hb A1 c,SBP,DBP and UA in the experimental group were significantly decreased compared with the control group,while RBC,HB and HCT were significantly increased compared with the control group,with statistical significance(P<0.05).However,there were no significant differences in body weight,TC,TG,HDL-C and LDL-C between the experimental group and the control group(P>0.05).(2)Body weight,BMI,FBG,2h PBG,Hb A1 c,SBP,DBP,TC,TG and UA of experimental groups were significantly decreased compared with before treatment,while HDL-C,RBC,HB and HCT were significantly increased compared with before treatment,with statistical significance(P<0.05).However,there was no significant change in LDL-C before and after treatment.(3)FBG,2h PBG and Hb A1 c in the control group were significantly decreased compared with before treatment,and the differences were statistically significant(P<0.05).However,there were no significant changes in body weight,BMI,SBP,DBP,RBC,HB,HCT,TC,TG,HDL-C,LDL-C and UA before and after treatment.(4)After 12 weeks of observation,no serious adverse reactions occurred in both groups.Conclusion:Representative drug of dagaglizin,SGLT-2i,can reduce FBG,2h PBG,Hb A1 c,SBP,DBP,BMI and UA,and increase RBC,HB and HCT in T2 DM patients with hypertension in Xining area.